Obesity as a Risk Factor in Covid-19 and the Possible Effect of Liraglutide Therapy
Year: 2020
Type: article
Abstract: Obesity is contributed to a growing awareness of the special needs of chronically overweight patients. Obesity poses significant pathophysiological, especially when patients are critically ill. Difficulties in obese patients in the intensive care unit ( ICU) often include difficulties with airway management, disordered ventilation and gas exchange, impaired circulation and altered drug efficacy, Altogether with the existence of rapidly evolving global epidemic of coronavirus disease (COVID-19) reveals that patients with obesity, at least in hospital, have a much worse prognosis. Moreover, it is becoming increasingly clear that there are more complex mechanisms through which obesity worsens the impact of COVID-19, resulting from metabolic and inflammatory alterations rather than simply the mechanical effects of increased fat tissue. Thus, the study of the relationship between obesity and severity of the disease is of great clinical importance. Here we summarize recent studies providing insights into the mechanism associated with obesity, insulin resistance and SARS-CoV-2 severity, and discuss the possible role of liraglutide in diminishing COVID19 severity in patients with obesity and insulin resistance.
Source: Journal of Critical Reviews
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W3131332395